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Abstract: The positive role of nutrition in chronic neurodegenerative diseases (NDs) suggests that
dietary interventions represent helpful tools for preventing NDs. In particular, diets enriched with
natural compounds have become an increasingly attractive, non-invasive, and inexpensive option
to support a healthy brain and to potentially treat NDs. Bioactive compounds found in vegetables
or microalgae possess special properties able to counteract oxidative stress, which is involved
as a triggering factor in neurodegeneration. Here, we briefly review the relevant experimental
data on curcuminoids, silymarin, chlorogenic acid, and compounds derived from the microalga
Aphanizomenon flos aquae (AFA) which have been demonstrated to possess encouraging beneficial
effects on neurodegeneration, in particular on Alzheimer’s disease models.
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1. Introduction
Chronic neurodegenerative diseases (NDs), such as dementia and its most frequent etiological
types—Alzheimer’s disease (AD) and Parkinson’s Disease (PD), are a growing cause of disability
and death, characterized by progressive loss or dysfunction of neurons in specific areas of the brain.
Patients with these disorders display variable clinical features including cognitive decline, speech
difficulties, and motor impairment [1]. In particular, AD is primarily a dementia-related disorder
characterized by a progressive decline in cognitive function and memory [2], while PD is primarily a
movement disorder illness with four major symptoms: tremor, slowness of movement, muscle rigidity,
and postural instability.
Neurodegenerative diseases represent a great public health concern and socioeconomic problem
because of the high mortality rates and healthcare costs for treatment and care assistance. Furthermore,
the current therapies for the treatment of AD and PD are only able to reduce the symptoms and
cannot arrest the development of neurodegeneration [3]. Therefore, more research needs to be
conducted to better understand the biochemical cascades of events resulting in neurodegeneration and
to discovery potential new neuroprotective drugs able to improve neuronal cell loss and restore brain
normal functioning.
Although AD and PD pathophysiology presents marked differences, some biochemical reactions
leading to neurodegeneration are shared by both diseases. The major pathological feature of AD
includes formation of amyloid plaques in extracellular spaces, caused by the deposition of the
amyloid-β (Aβ) peptide, derived by proteolytic cleavage of the amyloid protein precursor (APP),
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and intracellular neurofibrillary tangles (NFTs) [4,5]. Intracellular neurofibrillary tangles are composed
of hyperphosphorylated Tau proteins in neurons located particularly in the hippocampus and cerebral
cortex regions of the brain. The reduced expression of the brain-derived neurotrophic factor (BDNF),
important for neuronal growth and memory functions, also plays a crucial role in AD pathogenesis
via formation of senile plaque of Aβ and NFTs. At the molecular level, Aβ induces oxidative stress,
inflammation, and mitochondrial dysfunction associated with apoptosis [6,7].
Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the
substantia nigra (SN) and formation of Lewy bodies, abnormal intraneuronal aggregates of proteins
that include α-synuclein, ubiquitin, and neurofilaments [8]. The pathogenic mechanisms of PD include
oxidative stress, mitochondrial and protein dysfunction, inflammation, and apoptosis [9]. In particular,
oxidative stress generates ROS which activates glial cells, and activated glial cells generate inflammation
that results in mitochondrial dysfunction, and, consequently, dysfunctional mitochondria activate cell
death machinery [10].
Hence, oxidative stress and mitochondrial damage are common factors involved in the
etiopathology of these neurodegenerative diseases [11–13].
1.1. Oxidative Stress and Neurodegeneration
Oxidative stress is characterized by an overproduction of ROS—oxygen-containing molecules
known to be highly reactive.
Reactive oxygen species are formed in mitochondria during oxidative phosphorylation as a
byproduct of normal metabolism. Therefore, modest levels of ROS are normally expected and are
considered essential for the regulation of normal cell functions, while excessive ROS production can
damage various biological targets, such as DNA, lipids, and proteins, causing serious neurological injury.
Because the brain consumes a large amount of molecular oxygen to function properly, the accumulation
of damaged biomolecules caused by ROS is high, especially with aging [14]. To limit these cellular
damages, brain neurons produce antioxidant defense enzymes, such as superoxide dismutase (SOD),
glutathione peroxidase (GPX) and catalase (CAT), which neutralize the damaging effects of ROS
accumulation. The proper balance between oxidants and antioxidants can be disrupted with the
overproduction of free radicals. Overproduction of ROS in brain cells can lead to free radical attacks
against poly-unsaturated fatty acids (PUFAs) at the cell membrane which can, in turn, induce lipid
peroxidation [15]. Lipid peroxidation products, such as malondialdehyde (MDA) and hydroxynonenal
(4-HNE), are very toxic to neurons and can induce neuronal death [16]. Both AD and PD are usually
considered age-related neurodegenerative diseases due to the close relationship between ROS-induced
damage and aging.
1.2. Diet and Neurodegeneration
Lifestyle factors, such as obesity, physical inactivity, and unhealthy diet, are associated to the
increased risk of developing neurodegenerative disorders. In particular, high intakes of carbohydrates,
animal-based proteins, and saturated fats can promote increased ROS generation which, in turn,
is involved in the onset of obesity-related dysmetabolisms [17] including neurodegeneration [18].
Furthermore, a healthy diet contributes to the physiological development of the central nervous
system and participates in the maintenance of neuronal plasticity [19]. On the contrary, a wrong
and unbalanced diet can have a severe impact on brain function, thereby contributing to the onset
and worsening of neural dysfunctions. A recent work [20] showed that, in the brains of mice fed
with a hyperglycemic diet (HGD) or high-fat diet (HFD), changes occurred in the phosphorylation of
proteins involved in synaptic plasticity and neuronal functionality. In particular, dephosphorylation of
proteins involved in neuronal development (synaptic Ras GTPase-activating protein 1 (SYNGAP1) and
protein phosphatase 1 regulatory subunit 9B (PPP1R9B)), vesicle trafficking (clathrin-associated protein
(SNAP91) and amphiphysin (AMPH)), and in cytoskeletal functions (cytoplasmic linker-associated
protein 2 (CLASP2) and glycogen synthase kinase (3β-GSK3B)) was identified, while increased
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phosphorylation was detected for microtubule proteins (microtubule-associated protein 2 (MAP2) and
microtubule-associated protein Tau (MAPT)). The variation in phosphorylation of vesicle trafficking
and cytoskeletal proteins in the brain could be the cause of alterations in neuronal functions, being
correlated physiologically to axonal transport and pathologically to neurodegenerative disorders [20].
Then, this study confirms a connection between diet-induced obesity and impairment of neuronal
functions and signaling. In agreement, diets rich in fat and sugar (i.e., Western diet) have been linked
to the development of neurodegeneration [21], depression, and cognitive decline [22,23]. Indeed,
obesity and its comorbidities are considered risk factors for impaired cognitive performance and
cognitive decline. Increased body mass index (BMI) and waist circumference are negatively associated
with impaired memory performance [24], psychomotor function [25], and selective attention [26].
Obesity is also associated with decreased brain volume [27], in particular grey matter atrophy of the
temporal and frontal cortex and hippocampus [28,29] which represent the brain areas mainly affected
by morpho-functional damage in the early stage of AD [30].
Some evidence suggests that diet-induced obesity produces high levels of ROS in mice brains [31]
which, in turn, are associated with increased levels of AD biomarkers and inflammation [32,33].
Nuzzo and colleagues [18,34] demonstrated that, in HFD mice, obesity was associated with cerebral
increase in oxidative stress, mitochondrial dysfunction, APP expression, neuroinflammation, and
apoptosis. Another study confirmed that, the brain of HFD-fed obese mice prsent Aβ depositions,
dysregulations in neuronal apoptosis and autophagy activity, the latter being a cellular process which
allows to sustain cell viability when the exogenous nutrient supply is not available [35]. Several
studies [36,37] have reported that in different mouse models, the appearance of insulin resistance
causes the suppression of autophagy. A growing body of evidence shows that insulin resistance can
play an important role in the pathogenesis of AD [38]. Glucose is the main fuel of the brain, and glucose
uptake and utilization are stimulated by insulin. Insulin resistance leads to impairments in glucose
metabolism increasing oxidative stress, production of ROS, and mitochondrial dysfunction which drive
pro-apoptosis, pro-inflammatory, and pro-Aβ cascades [39]. Accordingly, obesity-related brain-specific
insulin resistance, known as type III diabetes [40,41], has been reported in dementia, including AD,
suggesting that it may contribute to neurodegeneration [42,43].
2. Dietary Natural Compounds and Neuroprotection
Growing evidence shows that certain dietary compounds, with neurogenic properties play a
beneficial role in brain aging and neurodegenerative disease [44–49]. In particular, compounds such as
polyphenols (i.e., flavonoids, curcuminoids, stilbenes, phenolic acids, carotenoids), abundant in various
alimentary sources (such as tea, red wine, herbs, seeds, and fruits), represent the phytochemicals
underlying the health effects associated to the constant consumption of fruits and vegetables.
Although the molecular mechanisms have yet to be established, polyphenols are able to induce
neurogenesis in the brain [49–52], reduce oxidative stress and neuroinflammation [53,54], and to enhance
cell signaling [55]. The potent antioxidant action of polyphenols takes place through scavenging of
free radicals and the consequent creation of more stable compounds [56].
A plethora of polyphenols have been investigated in relation to brain health. This review
summarizes the neuroprotective activities of curcuminoids, silymarin, and chlorogenic acids, for which
we recently explored the beneficial properties in preventing obesity-related neurodegeneration [57].
We delve into the efficacy of these natural compounds to counteract neuronal dysfunctions underlying
AD pathogenesis.
2.1. Curcuminoids
Curcuminoids are the most important group of chemical components of turmeric, a bright yellow
aromatic powder obtained from the rhizome of a plant belonging to the family Zingiberaceae
(Curcuma longa) and used to give flavor and color in Asian cooking. Curcuminoids include
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demethoxycurcumin, bisdemethoxycurcumin, and curcumin which are the main polyphenols of
Curcuma [58].
A large amount of in vitro and in vivo experiments using animal models suggest that curcuminoids
can exert neuroprotective effects. The main outcomes are summarized in Table 1.
In vitro studies have shown that curcuminoids are able to restore excitability in hippocampal CA1
neurons injured by exposure to Aβ peptides [59] and that curcumin is able to prevent Aβ-aggregation
and oligomer formation [60,61] by directly binding Aβ peptides [62]. Furthermore, curcumin positively
influences Aβ cellular uptake [63], preventing plaque deposition and avoiding cellular insults induced
by the peptides [64]. It can also downregulate Aβ production by suppressing β amyloid-induced
BACE-1 (beta-site APP-cleaving enzyme) upregulation [65]. A recent study has shown that curcumin
downregulates the expression of amyloid precursor protein and amyloid-β in swAPP695-HEK293 cells
through the increase of miR-15b-5p expression. The microRNA seems to target the 3’-untranslated
region of amyloid precursor protein leading to silencing of APP expression [66].
In vivo administration of curcuminoids is able to enhance spatial learning and memory in rats
displaying AD-like neurodegeneration [67], while curcumin administration is able to rescue the
Aβ-related neurite morphological changes that occur near plaques [68] and to reduce brain Aβ burden
as well as inflammation and microglia activation in AD mouse models [69]. Ishrat and colleagues [70]
demonstrated that curcumin supplementation decreases cognitive behavior and the biochemical and
histopathological alterations in the brain of intracerebroventricular (CV)-streptozotocin (STZ)-infused
rats by reducing MDA and H2O2 levels and increasing the concentrations of glutathione (GSH)
and GSH-dependent antioxidant enzymes (glutathione peroxidase and glutathione reductase) in the
hippocampus and cerebral cortex [70].
Lim et al. [71] verified that administration of a curcumin diet significantly reduced inflammatory
marker expression, such as IL-1β and glial fibrillary acidic protein (GFAP), and oxidized the protein
concentration and the overall insoluble Aβ, soluble Aβ, and plaque burden in the brains of Alzheimer
transgenic APP mouse model [71]. Moreover, curcumin intake was shown to reduce amyloid levels in
Tg2576 mice with advanced amyloid accumulation.
A recent study analyzed the effects of a natural dietary supplement (NDS) containing
Curcuma longa and other plant phenolic extracts, such as silymarin, guggul, chlorogenic acid, and inulin,
on dysmetabolism and neurodegeneration in the brains of a diet-induced obesity mouse model.
After 16 weeks of a hyper-lipidic diet with NDS, ROS concentration, lipid peroxidation, and expression
of oxidative stress markers (p-ERK, H-Oxy, i-NOS, and HSP60) were significantly reduced in the brains
of NDS-treated HFD mice in comparison with untreated obese mice, suggesting antioxidant effects
of NDS. In addition, NDS was able to prevent neuronal apoptosis. In fact, a tunnel assay showed
that in brain cortical sections of NDS-treated HFD mice, the number of neurons with fragmented
DNA (index of an impairment of cell survival) was significantly reduced compared to HFD untreated
animals [57]. The beneficial effects of NDS are probably due to the well-documented anti-oxidative
actions of curcumin, although a synergistic action of all polyphenolic compounds contained in NDS
has to also be considered. In fact, antioxidant and neuroprotective effects have been reported for
silymarin and chlorogenic acid as well [72,73]. Figure 1 summarizes the main actions responsible for
the neuroprotective effects of curcuminoids.
Despite the beneficial effects of curcumin in animal models, the available clinical studies are not
enough to confirm the protective effect of curcumin for a patient’s treatment.
Epidemiologic studies have suggested that large amounts of curcumin intake are related to better
cognitive function in healthy elderly individuals and a lower incidence of AD [74,75]. Furthermore,
the expression of Aβ42, an Aβ form mainly involved in the early pathogenesis of the disease, is strongly
reduced in the cerebro-spinal fluid of AD patients eating a diet rich in curcumin [76].
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NO: nitric oxide; COX: cyclooxygenase; ER-β: estrogen receptor-β; BDNF: brain-derived neurotrophic 
factor; AChE: acetylcholinesterase. 
Despite the beneficial effects of curcumin in animal models, the available clinical studies are not 
enough to confirm the protective effect of curcumin for a patient’s treatment. 
Epidemiologic studies have suggested that large amounts of curcumin intake are related to 
better cognitive function in healthy elderly individuals and a lower incidence of AD [74,75]. 
Furthermore, the expression of Aβ42, an Aβ form mainly involved in the early pathogenesis of the 
disease, is strongly reduced in the cerebro-spinal fluid of AD patients eating a diet rich in curcumin 
[76]. 
Nevertheless, clinical trials revealing any beneficial effects of curcuminoid administration for 
the treatment of AD are few and controversial [77–79]. The negative findings seem to be related to 
the low bioavailability of curcuminoids and the poor design of the clinical trials. More clinical studies 
with larger sample sizes and longer treatment durations should be designed to evaluate the effects 
of new formulations of curcumin with better bioavailability. 
2.2. Silymarin 
Silymarin is a mixture of flavonolignans, flavonoids, and other polyphenolic compounds 
extracted from milk thistle (Silybum marianum), an annual or a biennial plant belonging to the 
Asteraceae family and widely cultivated in the Mediterranean region. Silymarin is considered a 
scavenger of free radicals [80], and it is widely used in the treatment of liver discomfort. Moreover, 
silymarin is capable of protecting the central nervous system against injury and memory impairment 
[81,82]. Evidence for the neuroprotective action of silymarin has been reported both in animal models 
of neurodegenerative diseases [83,84] (Table 1) and in neuronal and non-neuronal cellular models 
[85–87]. The ability to slow the progression of neurodegeneration was also tested in CL4176 
Caenorhabditis elegans, a model for AD. The results demonstrated that silymarin treatment 
significantly reduced the expression of amyloid β-protein (Aβ1-42) in muscle tissues of C. elegans via 
enhancing resistance to oxidative stress [72]. In rats, silymarin administration can improve ethanol-
Figure 1. Schematic representation of the main actions responsible for the neuroprotective and
neurotrophic effects of curcumi oids, silymarin, a d Chlorogenic acids (CGA) i the brain. In general,
the compounds inhibit oxidative and nitrosative stress, prevent formation of Aβ aggregates and fibrils,
and r duce expre sion and activity of inflammatory agent , leading to less neur inflammation and glial
activation, decreasing apopt sis, increasing BDNF, inhibiting AChE, a d binding ER-β, (T indicates
inhibitory effects). TNF-a: tumor necrosis factor-a; NFkB: nuclear factor kappa light-chain enhancer of
activated B cells; TNF-β, tumor necrosis factor-β; iNOS: inducible nitric oxide synthase; NO: nitric
oxide; COX: cyclooxygenase; ER-β: estrogen receptor-β; BDNF: brain-derived neurotrophic factor;
AChE: acetylcholinesterase.
Nevertheless, clinical trials revealing any beneficial effects of curcuminoid administration for the
treatment of AD are few and controversial [77–79]. The negative findings seem to be related to the low
bioavailability of curcuminoids and the poor design of the clinical trials. More clinical studies with
larger sample sizes and longer treatment durations should be designed to evaluate the effects of new
formulations of curcumin with better bioavailability.
2.2. Silymarin
Silymarin is a mixture of flavonolignans, flavonoids, and other polyphenolic compounds extracted
from milk thistle (Silybum marianum), an annual or a biennial plant belonging to the Asteraceae family
and widely cultivated in the Mediterranean regi n. Silymarin is considered a scavenger of free
radicals [80], and it is widely used in the treatment of liver discomfort. Mor over, silymarin is capable
of prot cting the central nervous system against injury and memory impairment [81,82]. Evidence for
the neuroprotective action of silymarin has been reported both in animal models of neurodegenerative
diseases [83,84] (Table 1) and in neuronal and non-neuronal cellular models [85–87]. The ability to
slow the progression of neurodegeneration was also tested in CL4176 Caenorhabditis elegans, a model
for AD. The results demonstrated that silymarin treatment significantly reduced the expression of
amyloid β-protein (Aβ1-42) in m scle tissues of C. elegans via enha cing resistance to oxidative
stress [72]. In rats, silymarin administration can improve ethanol-induce learning deficits [88]
or prevent lipopolysaccharide and oxidative stress induced-neurotoxicity [89]. In APP transgenic
mice, chronic silymarin treatment (half a year) improved AD-like phenotypes; in fact, it significantly
reduced the cerebral plaque burden and brain microglial activation associated with an improvement
of the behavioral abnormalities induced by AD pathology [86]. The molecular pathway of the
neuroprotective potential of silymarin has mainly been ascribed to its capacity to inhibit oxidative
stress in the brain [84,89], but different mechanisms, such as inhibition of the inflammatory response
linked to neurodegeneration [90], neurotropic effects [91], inhibition of apoptosis [92] and regulation
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of neurotransmitters [93], have also been involved (Figure 1). More specifically, silymarin has been
reported to attenuate neuronal damage in the hippocampus of Aβ1-42-injected rats by upregulating the
brain-derived neurotrophic factor (BDNF)/ tyrosine receptor kinase B (TrkB) pathway and attenuating
neuronal apoptosis [91]. It can improve learning and memory in diabetic rats by increasing BDNF
levels [94]. Moreover, several studies report that the underlying mechanisms of the silymarin-induced
neuroprotective effects may be due to the fact of its estrogen-like activity [95] as well as its potential to
bind and activate ER-β [83,96].
Multiple findings obtained via in vitro and in vivo studies suggest that silymarin’s neuroprotective
activity may be due the presence of silibinin which is its major pharmacologically active compound.
Silibinin is able to attenuate oxidative stress-induced brain dysfunctions because of its potent
antioxidative activity mainly related to the scavenging of free radicals [97,98] and increase in cellular
GSH content [99] and SOD levels [100]. In addition, silibinin can inhibit Aβ aggregation in vitro
and protect SH-SY5Y neuroblastoma cells from injuries caused by Aβ1-42-induced oxidative stress
through a decrease in H2O2 production [85]. Silibinin can inhibit the activation of aging-related
proteins and excessive ROS production in D-galactose-induced senescent mice [101], and it can
protect against Aβ-induced neurotoxicity [102]. In particular, silibinin treatment attenuates memory
impairment in intracerebroventricularly Aβ25-35-injected mice by reducing nitrotyrosine, iNOS, and
TNF-α levels, and by increasing GSH levels in the hippocampus [84,102]. In the brain of APP/PS1
Tg mice, silibinin can reduce the amount of soluble and insoluble aβ40 and aβ42 and decrease
the deposition of amyloid plaque and promote neurogenesis. These effects are associated with the
inhibition of acetylcholinesterase activity and improvement in learning and memory deficits [93].
A further study showed that silibinin treatment significantly reduced MDA, ROS, GSH, and nitrite
levels, strictly associated with STZ-induced memory impairment, and strongly counteracted the
increase of acetylcholinesterase (AChE) and the decrease of α-7nicotinic acetylcholine receptor mRNA
expression in IC-STZ-mouse brains, suggesting that the beneficial effect may be due to the improvement
in brain energy metabolism and cholinergic function [103]. Recently, silibinin and silymarin have been
shown to alleviate memory impairment of transgenic APP/PS1 mice through regulation of the gut
microbiota. In fact, silibinin and silymarin administration modified the relative abundance of several
bacterial species associated with AD [104]. However, it is necessary to underline that there is a lack of
translational research and clinical evidence for these promising flavonoids which could be useful for
treating neurodegenerative diseases [105].
2.3. Chlorogenic Acids
Another polyphenolic substance with excellent antioxidant activity is chlorogenic acid (CA),
the major phenolic component in coffee. Chlorogenic acid belongs to the family of chlorogenic acids
(CGAs), phenolic acids derived from the esterification of cinnamic acids including caffeic, ferulic,
and p-coumaric acids. Besides coffee, CGAs are widely present in beverages prepared from herbs,
fruits, and vegetables. The health benefits of consuming coffee, tea, and vegetable juice may be
linked, at least in part, to their content of CGAs. Chlorogenic acids exhibit antibacterial, antioxidant,
and anti-inflammatory activities [106].
Different in vitro and in vivo studies have highlighted the ability of CA or its derivatives to
counteract neurodegenerative events (Table 1).
In vitro, CA is able to protect different types of neuronal cells from apoptosis and induced-
oxidative neurotoxicity by blocking intracellular ROS accumulation, GSH depletion, MAPK, BACE-1,
and α-secretase activation [107,108]. Chlorogenic acid can also counteract neuronal apoptosis in rat
brain by inhibiting AChE and butyrilcholinesterase (BChE) activity, responsible for cholinergic deficits
associated with memory loss of AD [109,110], and reducing pro-oxidant (FeSO4, sodium nitroprusside
and quinolinic acid)-induced MDA [111]. Han et colleagues [112] demonstrated that CGA also has
neuroprotective effects on Aβ-treated neuroblastoma SH-SY5Y cells through the upregulation of
phosphoglycerate kinase-1 (PGK1) expression and the activation of ATP production. Accordingly,
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CA and its derivatives, 4,5-di-O-caffeoylquinic acid (4,5-di-CQA) and 3,4,5-tri-O-caffeoylquinic acid
(3,4,5-tri-CQA), are able to counteract the aggregation of Aβ42 and its neurotoxicity on human
neuroblastoma SH-SY5Y cells. The results of this study showed that 4,5-di-CQA and 3,4,5-tri-CQA
inhibited the aggregation of Aβ42 in a dose-dependent manner by suppressing the radical-mediated
aggregation of Aβ42 [113].
Table 1. Summary of the main findings on the potential beneficial effects of curcuminoids, silymarin,
and chlorogenic acids against neurodegeneration.
Outcome Type of Study Natural Compounds
Prevention of neurodegeneration [57]. Mice Curcuma longa, Silymarin, Guggul,Chlorogenic Acid, and Inulin
Enhancement of memory [67]. Rats Curcuminoids
Disruption of existing plaques and restoration of distorted neuritis [68]. Mice Curcumin
Prevention of amyloid-beta deposition and attenuation inflammation in brain [69]. Mice Curcumin
Amelioration of cognitive deficits and neurodegeneration [70]. Rats Curcumin
Reduction oxidative damage and amyloid pathology [71]. Mice Curcumin
Improvement in cognitive function and lower incidence of Alzheimer’s disease
(AD) [74]. Epidemiological study Curcumin
Reduction of Aβ42 expression in the cerebro-spinal fluid [75]. Epidemiological study Curcumin
Improvement of the behavioral symptoms in AD [78]. Epidemiological study Curcumin
Neuroprotective effects by reduction of oxidative stress [83,84,89]. Rats and mice Silymarin
Attenuation of amyloid β plaque burden and improvement of behavioral
abnormalities [86]. Mice Silymarin
Dopaminergic neuron protection through inhibiting microglia activation,
inflammation, and apoptosis [87,90]. Rats Silymarin
Prevention of social learning deficits [88]. Rats Silymarin
Neuroprotection by upregulation of neurotrophic factors and attenuation of
autophagy, oxidative stress, and apoptosis [91,92]. Rats Silibinin
Downregulation of acetylcholinesterase (AChE) activity and Aβ aggregation [93]. Mice Silibinin
Improvement in learning and memory by increasing the brain-derived neurotrophic
factor BDNF levels [94]. Rats Silymarin
Neuroprotective effect due to the estrogen-like activity through selective activation
of ERβ [95,96]. Rats Silymarin
Increase of the glutathione content [99]. Rats Silymarin
Prevention of memory impairment by reducing oxidative stress and Aβ
aggregation [85,102] Mice Silibinin
Protection against senescence by inhibiting NF-kappaB activation and ROS
production [101]. Mice Silymarin
Improvement of memory impairment by increasing brain energy metabolism and
cholinergic functions [103]. Mice Silibinin
Regulative effects on relative abundance of several key bacterial species involved in
AD development [104]. Mice Silymarin and Silibinin
Protective effect against AD. Pathogenesis via modulating cerebral insulin signaling,
β-Amyloid accumulation, and synaptic plasticity [114]. Rats Caffeic Acid
Neuroprotective effects via anti-acetylcholinesterase and anti-oxidative
activities [115]. Mice Chlorogenic Acid
Prevention of cognitive dysfunction and suppression of amyloid β plaques [116]. Mice Chlorogenic Acid
Reduction of mild cognitive impairment and AD risk [117,118]. Epidemiological study Coffee
Decrement of amyloid pathology [119]. Epidemiological study Coffee
Lower risk of dementia and AD later in life [120]. Epidemiological study Coffee
Improvement of attentional, executive, and memory functions [121]. Human Chlorogenic Acid
Improvement of cognitive functions including motor speed, psychomotor speed, and
executive functions [122]. Human Chlorogenic Acid
The protective effects of CGA on brain health and cognitive impairment have been evaluated
using AD animal models. Chang et colleagues [114] showed the alleviative effect of CA on AD
pathogenesis in HF diet-induced hyper-insulinemic rats. In particular, administration of CA for
30 weeks significantly ameliorated memory and learning impairments, cerebral insulin signaling,
β-amyloid accumulation, and synaptic plasticity [114]. Chlorogenic acid also exerts anti-amnesic
activity in mice with scopolamine-induced learning and memory deficits via inhibition of AChE and
MDA in the hippocampus and frontal cortex [115]. A recent work investigated whether treatment with
coffee polyphenols (CPPs) was able to prevent or reduce progressive impairments in memory and
cognitive function in APP/PS2 mice, a model of AD. The results showed that CPP treatment prevented
cognitive dysfunction by reducing amyloid Aβ plaques in the hippocampus due to the disaggregation
of the fibrillar Aβ species into Aβ peptides [116].
To date, few studies have analyzed the effects of CGA on human cognitive impairment.
Epidemiological studies found that coffee consumption habits may reduce the risk of mild cognitive
impairment and AD [117,118]. The healthy benefits seem to be linked to CA antioxidant and
anti-inflammatory properties (Figure 1). One study investigated the relationships between coffee intake
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and in vivo AD pathologies, including cerebral Aβ deposition, the neurodegeneration of AD signature
regions, and cerebral white matter hyper intensities. The results showed that lifetime coffee intake
of ≥2 cups/day was significantly associated with a lower Aβ positivity compared to coffee intake of
<2 cups/day, suggesting that higher lifetime coffee intake may contribute to lowering the risk of AD or
related cognitive decline by reducing pathological cerebral amyloid deposition [119]. Similar results
were achieved by Eskelinen et al. [120]. They observed that coffee drinkers at midlife had lower risk of
dementia and AD later in life compared with those drinking no or only little coffee. Kato et al. [121]
reported that six-month intake of CGAs improved attentional, executive, and memory functions in the
elderly with complaints of subjective memory loss. It is interesting to note that CGAs may improve
some of the cognitive functions included in the CNS Vital Signs (Cognitrax) score, such as motor speed,
psychomotor speed, and executive functions, in healthy individuals [122]. However, human studies
have mainly investigated if coffee consumption improves cognitive performance, but its components
have not been studied individually.
3. New Frontiers in Nutritional Prevention: Microalgal-Derived Extracts
Another class of natural compounds with strong neuroprotective potential and which is relatively
unexplored yet is represented by extracts and biologically active compounds derived from microalgal
biomass [123].
Microalgae are unicellular photosynthetic micro-organisms, living in saline or freshwater
environments. They exist as eukaryotes, similar to green algae, or prokaryotes, similar to
cyanobacteria [124]. The blue-green algae Spirulina, Chlorella, and Aphanizomenon flos aquae (AFA)
are unicellular prokaryotic microorganisms belonging to the Cyanobacteria phylum. They are
excellent sources of various biologically active compounds such as sterols, PUFAs, proteins,
carotenoids, and polysaccharides [125]. Several experimental investigations have highlighted the
anti-inflammatory [126], anticancer [127], and antioxidant [128–131] properties of microalgal-derived
extracts and different studies have investigated the neuroprotective potentials of microalgae compounds
against AD, mainly focusing on oxidative stress or β-amyloid aggregation. It has been reported that
Chlorella vulgaris attenuate lead-induced oxidative damage in rats’ brains via an increase SOD, CAT,
and GPX expressions as well as a reduction of MDA levels [132] and that Chlorella sp. and Spirulina
sp. extracts exhibit antioxidant protection in rats’ brain homogenates [133]. Spirulina maxima also
scavenged hydroxyl radicals and inhibited lipid peroxidation thanks to its phenolic extracts [134].
Biochanin A, an isoflavone identified in Chlorella vulgaris, exhibited neuroprotective activity against
Aβ-induced neurotoxicity in neuroblastoma cell culture [135].
The Aphanizomenon flos aquae Ralfs ex Born. & Flah. var. flos aquae (AFA) species is a peculiar
variety of blue-green microalgae that lives and proliferates in the Upper Klamath Lake (Oregon,
USA). Due to the volcanic origin of the lake, Klamath AFA contain a peculiar pattern of macro- and
micronutrients. In particular, AFA extracts are a rich source of vitamin B12, essential for myelin
formation; trace minerals [136], such as molybdenum and tungsten, important antioxidant enzymes
cofactors [137,138]; and pigments, such as carotene, beta-carotene, chlorophylls, and phycocyanins
with well-known antioxidant and anti-inflammatory [139] properties.
A recent in vitro study analyzed the effects of the Klamath AFA extract (Klamin®) on oxidative
stress and neurodegeneration in a neuronal LAN5 cell model. The results showed that Klamin®
was able to inhibit neuronal toxicity induced by the oxidant agent tert-butylhydroperoxide (TBH).
This protective effect was mediated by scavenging activity, because the treatment with Klamin®
significantly decreased ROS generation in TBH-treated cells. Klamin® was also able to prevent
TBH-induced mitochondrial dysfunction, suggesting that its antioxidant capability can be extended to
mitochondrial ROS. Furthermore, Klamin® exerted a protective role against neuronal toxicity induced
by Aβ-peptide. In particular, AFA extract interfered with Aβ aggregation by inhibiting its extension,
producing aggregates of shorter dimensions, and destabilizing the preformed fibrils. Furthermore,
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the AFA extract exerted anti-inflammatory activity consequent to Aβ toxic stimulus, decreasing the
production of proinflammatory cytokines such as IL-6 and IL-1β [140,141].
4. Conclusions
In conclusion, dietary interventions can be helpful tools for preventing or reversing the course of
neurodegenerative diseases. Polyphenols are able to exert positive effects on brain health by enhancing
neuronal function. The mechanisms of action of curcuminoids, silymarin, and chlorogenic acid can
provide a defense against many pathophysiological features of neurodegenerative diseases such as
oxidative stress, mitochondrial dysfunction, neuroinflammation, and protein aggregation. These
natural products have proven to be promising for neurodegeneration and AD therapy in preclinical
studies. Currently, clinical trials have shown inconsistent results, suggesting that further studies are
necessary to uncover their therapeutic potential. Clinical studies have probably failed to succeed
because treatment starts when the patients are already in an advanced state of the disease. A nutritional
approach may circumvent this problem. The supplementation of bioactive natural compounds may
start at a young age, allowing both prevention and a delay in disease progression. However, their
bioavailability in the brain, including the ability to cross the blood–brain barrier, is yet to be established
and remains one of the main obstacles for the development of therapies.
Author Contributions: Writing—original draft preparation, A.A.; writing, figure and table preparation, S.T.;
writing—review and editing, F.M.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Yacoubian, T.A. Neurodegenerative disorders: Why do we need new therapies? In Drug Discovery Approaches
for the Treatment of Neurodegenerative Disorders; Adejare, A., Ed.; Academic Press: London, UK, 2017; pp. 1–16.
2. Robinson, M.; Lee, B.Y.; Hane, F.T. Recent progress in Alzheimer’s disease research, part 2: Genetics and
epidemiology. J. Alzheimers Dis. 2017, 57, 317–330. [CrossRef] [PubMed]
3. Sosa-Ortiz, A.L.; Acosta-Castillo, I.; Prince, M.J. Epidemiology of dementias and Alzheimer’s disease. Arch.
Med. Res. 2012, 43, 600–608. [CrossRef] [PubMed]
4. Selkoe, D.J. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends
Cell Biol. 1998, 8, 447–453. [CrossRef]
5. Cole, S.L.; Vassar, R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol. Neurodegener. 2007, 2,
1–25. [CrossRef] [PubMed]
6. Picone, P.; Carrotta, R.; Montana, G.; Nobile, M.R.; San Biagio, P.L.; Di Carlo, M. Aβ oligomers and fibrillar
aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys. J. 2009, 96,
4200–4211. [CrossRef]
7. Picone, P.; Giacomazza, D.; Vetri, V.; Carrotta, R.; Militello, V.; San Biagio, P.L.; Di Carlo, M. Insulin-activated
Akt rescues Aβ oxidative stress-induced cell death by orchestrating molecular trafficking. Aging Cell 2011,
10, 832–843. [CrossRef] [PubMed]
8. Olanow, C.W.; Wakeman, D.R.; Kordower, J.H. Peripheral alpha-synuclein and Parkinson’s disease. Mov.
Disord. 2014, 29, 963–966. [CrossRef] [PubMed]
9. Corona, J.C.; Duchen, M.R. PPAR and PGC-1α as therapeutic targets in Parkinson’s. Neurochem. Res. 2015,
40, 308–316. [CrossRef]
10. Levy, O.A.; Malagelada, C.; Greene, L.A. Cell death pathways in Parkinson’s disease: Proximal triggers,
distal effectors, and final steps. Apoptosis 2009, 14, 478–500. [CrossRef]
11. 00 Crunkhorn, S. Neurodegenerative disorders: Restoring the balance. Nat. Rev. Drug Discov. 2011, 10, 576.
[CrossRef]
12. Sas, K.; Robotka, H.; Toldi, J.; Vécsei, L. Mitochondria, metabolic disturbances, oxidative stress and the
kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257, 221–239. [CrossRef]
[PubMed]
Antioxidants 2019, 8, 608 10 of 16
13. Bishop, N.A.; Lu, T.; Yankner, B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464,
529–535. [CrossRef] [PubMed]
14. Halliwell, B. Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006, 97, 1634–1658.
[CrossRef] [PubMed]
15. Rahman, K. Studies on free radicals, antioxidants, and co-factors. Clin. Interv. Aging 2007, 2, 219–236.
[PubMed]
16. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms
of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 2014, 360438. [CrossRef]
17. Tan, B.L.; Norhaizan, M.E.; Liew, W.P. Nutrients and Oxidative Stress: Friend or Foe? Oxid. Med. Cell. Longev.
2018, 2018, 9719584. [CrossRef]
18. Nuzzo, D.; Baldassano, S.; Amato, A.; Picone, P.; Galizzi, G.; Caldara, G.F.; Di Carlo, M.; Mulè, F. Glucagon-like
peptide-2 reduces the obesity-associated inflammation in the brain. Neurobiol. Dis. 2019, 121, 296–304.
[CrossRef]
19. Dauncey, M.J. Nutrition, the brain and cognitive decline: Insights from epigenetics. Eur. J. Clin. Nutr. 2014,
68, 1179–1185. [CrossRef]
20. Siino, V.; Amato, A.; Di Salvo, F.; Caldara, G.F.; Filogamo, M.; James, P.; Vasto, S. Impact of diet-induced
obesity on the mouse brain phosphoproteome. J. Nutr. Biochem. 2018, 58, 102–109. [CrossRef]
21. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185.
[CrossRef]
22. Dipnall, J.F.; Pasco, J.A.; Meyer, D.; Berk, M.; Williams, L.J.; Dodd, S.; Jacka, F.N. The association between
dietary patterns, diabetes and depression. J. Affect. Disord. 2015, 174, 215–224. [CrossRef] [PubMed]
23. Gomes, F.A.; Kauer-Sant’Anna, M.; Magalhães, P.V.; Jacka, F.N.; Dodd, S.; Gama, C.S.; Cunha, A.; Berk, M.;
Kapczinski, F. Obesity is associated with previous suicide attempts in bipolar disorder. Acta Neuropsychiatr.
2010, 22, 63–67. [CrossRef] [PubMed]
24. Coppin, G.; Nolan-Poupart, S.; Jones-Gotman, M.; Small, D.M. Working memory and reward association
learning impairments in obesity. Neuropsychologia 2014, 65, 146–155. [CrossRef] [PubMed]
25. Cournot, M.; Marquié, J.C.; Ansiau, D.; Martinaud, C.; Fonds, H.; Ferrières, J.; Ruidavets, J.B. Relation
between body mass index and cognitive function in healthy middle-aged men and women. Neurology 2006,
67, 1208–1214. [CrossRef]
26. Fergenbaum, J.H.; Bruce, S.; Lou, W.; Hanley, A.J.; Greenwood, C.; Young, T.K. Obesity and lowered cognitive
performance in a Canadian first nations population. Obesity 2009, 17, 1957–1963. [CrossRef]
27. Ward, M.A.; Carlsson, C.M.; Trivedi, M.A.; Sager, M.A.; Johnson, S.C. The effect of body mass index on
global brain volume in middle-aged adults: A cross sectional study. BMC Neurol. 2005, 5, 23. [CrossRef]
28. Shefer, G.; Marcus, Y.; Stern, N. Is obesity a brain disease? Neurosci. Biobehav. Rev. 2013, 37, 2489–2503.
[CrossRef]
29. Gunstad, J.; Paul, R.H.; Cohen, R.A.; Tate, D.F.; Spitznagel, M.B.; Grieve, S.; Gordon, E. Relationship between
body mass index and brain volume in healthy adults. Int. J. Neurosci. 2008, 118, 1582–1593. [CrossRef]
30. Flores-Martínez, E.; Peña-Ortega, F. Amyloid β Peptide-Induced Changes in Prefrontal Cortex Activity and
Its Response to Hippocampal Input. Int. J. Pept. 2017, 2017, 7386809. [CrossRef]
31. Freeman, L.R.; Zhang, L.; Nair, A.; Dasuri, K.; Francis, J.; Fernandez-Kim, S.O.; Bruce-Keller, A.J.; Keller, J.N.
Obesity increases cerebrocortical reactive oxygen species and impairs brain function. Free Radic. Biol. Med.
2013, 56, 226–233. [CrossRef]
32. Kothari, V.; Luo, Y.; Tornabene, T.; O’Neill, A.M.; Greene, M.W.; Geetha, T.; Babu, J.R. High fat diet induces
brain insulin resistance and cognitive impairment in mice. Biochim. Biophys. Acta 2017, 1863, 499–508.
[CrossRef] [PubMed]
33. Martins, I.V.A.; Rivers-Auty, J.; Allan, S.M.; Lawrence, C.B. Mitochondrial abnormalities and synaptic loss
underlie memory deficits seen in mouse models of obesity and Alzheimer’s disease. J. Alzheimers Dis. 2017,
55, 915–932. [CrossRef] [PubMed]
34. Nuzzo, D.; Picone, P.; Baldassano, S.; Caruana, L.; Messina, E.; Marino Gammazza, A.; Cappello, F.; Mulè, F.;
Di Carlo, M. Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease.
Curr. Alzheimer Res. 2015, 12, 723–735. [CrossRef] [PubMed]
Antioxidants 2019, 8, 608 11 of 16
35. Busquets, O.; Ettcheto, M.; Pallàs, M.; Beas-Zarate, C.; Verdaguer, E.; Auladell, C.; Folch, J.; Camins, A.
Long-term exposition to a high fat diet favors the appearance of β-amyloid depositions in the brain of
C57BL/6J mice. A potential model of sporadic Alzheimer’s disease. Mech. Ageing Dev. 2017, 162, 38–45.
[CrossRef] [PubMed]
36. Kim, H.G. Cognitive dysfunctions in individuals with diabetes mellitus Yeungnam. Univ. J. Med. 2019, 36,
183–191.
37. Yoshizaki, T. Autophagy in insulin resistance. Anti-Aging Med. 2012, 9, 180–184.
38. Kadohara, K.; Sato, I.; Kawakami, K. Diabetes mellitus and risk of early-onset Alzheimer’s disease:
A population-based case-control study. Eur. J. Neurol. 2017, 24, 944–949. [CrossRef]
39. De la Monte, S.M.; Longato, L.; Tong, M.; Wands, J.R. Insulin resistance and neurodegeneration: Roles of
obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr. Opin. Investig. Drugs 2009, 10,
1049–1060.
40. Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M.
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s
disease—Is this type 3 diabetes? J. Alzheimers Dis. 2005, 7, 63–80. [CrossRef]
41. Rivera, E.J.; Goldin, A.; Fulmer, N.; Tavares, R.; Wands, J.R.; de la Monte, S.M. Insulin and insulin-like growth
factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions
in acetylcholine. J. Alzheimers Dis. 2005, 8, 247–268. [CrossRef]
42. Ghareeb, D.A.; Hafez, H.S.; Hussien, H.M.; Kabapy, N.F. Non-alcoholic fatty liver induces insulin resistance
and metabolic disorders with development of brain damage and dysfunction. Metab. Brain Dis. 2011, 26,
253–267. [CrossRef] [PubMed]
43. De Felice, F.G.; Lourenco, M.V. Brain metabolic stress and neuroinflammation at the basis of cognitive
impairment in Alzheimer’s disease. Front. Aging Neurosci. 2015, 7, 94. [CrossRef] [PubMed]
44. Poddar, J.; Pradhan, M.; Ganguly, G.; Chakrabarti, S. Biochemical deficits and cognitive decline in brain
aging: Intervention by dietary supplements. J. Chem. Neuroanat. 2019, 95, 70–80. [CrossRef] [PubMed]
45. Oliveira, P.S.; Chaves, V.C.; Soares, M.S.P.; Bona, N.P.; Mendonça, L.T.; Carvalho, F.B.; Gutierres, J.M.;
Vasconcellos, F.A.; Vizzotto, M.; Vieira, A.; et al. Southern Brazilian native fruit shows neurochemical,
metabolic and behavioral benefits in an animal model of metabolic syndrome. Metab. Brain Dis. 2018, 33,
1551–1562. [CrossRef] [PubMed]
46. Naoi, M.; Inaba-Hasegawa, K.; Shamoto-Nagai, M.; Maruyama, W. Neurotrophic function of phytochemicals
for neuroprotection in aging and neurodegenerative disorders: Modulation of intracellular signaling and
gene expression. J. Neural. Transm. 2017, 124, 1515–1527. [CrossRef] [PubMed]
47. Caruana, M.; Cauchi, R.; Vassallo, N. Putative Role of Red Wine Polyphenols against Brain Pathology in
Alzheimer’s and Parkinson’s Disease. Front. Nutr. 2016, 12, 3–31. [CrossRef]
48. Dohrmann, D.D.; Putnik, P.; Bursac´ Kovacˇevic´, D.; Simal-Gandara, J.; Lorenzo, J.M.; Barba, F.J. Japanese,
Mediterranean and Argentinean diets and their potential roles in neurodegenerative diseases. Food Res. Int.
2019, 120, 464–477. [CrossRef]
49. Winner, B.; Winkler, J. Adult neurogenesis in neurodegenerative diseases. Cold Spring Harb. Perspect. Biol.
2015, 7, a021287. [CrossRef]
50. Beltz, B.S.; Tlusty, M.F.; Benton, J.L.; Sandeman, D.C. Omega-3 fatty acids upregulate adult neurogenesis.
Neurosci. Lett. 2007, 415, 154–158. [CrossRef]
51. Kim, S.J.; Son, T.G.; Park, H.R.; Park, M.; Kim, M.S.; Kim, H.S.; Chung, H.Y.; Mattson, M.P.; Lee, J. Curcumin
stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus.
J. Biol. Chem. 2008, 283, 14497–14505. [CrossRef]
52. Bhullar, K.S.; Rupasinghe, H. Polyphenols: Multipotent therapeutic agents in neurodegenerative diseases.
Oxid. Med. Cell. Longev. 2013, 2013, 891748. [CrossRef] [PubMed]
53. Dauncey, M.J. Genomic and epigenomic insights into nutrition and brain disorders. Nutrients 2013, 5, 887–914.
[CrossRef] [PubMed]
54. Gomez-Pinilla, F. Brain foods: The effects of nutrients on brain function. Nat. Rev. Neurosci. 2008, 9, 568–578.
[CrossRef] [PubMed]
55. Poulose, S.M.; Carey, A.N.; Shukitt-Hale, B. Improving brain signaling in aging: Could berries be the answer?
Expert Rev. Neurother. 2012, 12, 887–889. [CrossRef]
Antioxidants 2019, 8, 608 12 of 16
56. Rossi, L.; Mazzitelli, S.; Arciello, M.; Capo, C.R.; Rotilio, G. Benefits from dietary polyphenols for brain aging
and Alzheimer’s disease. Neurochem. Res. 2008, 33, 2390–2400. [CrossRef]
57. Nuzzo, D.; Amato, A.; Picone, P.; Terzo, S.; Galizzi, G.; Bonina, F.P.; et al. A Natural Dietary Supplement with
a Combination of Nutrients Prevents Neurodegeneration Induced by a High Fat Diet in Mice. Nutrients 2018,
10, 1130. [CrossRef]
58. Kamran, A.; Sadia, S. A comprehensive review on Curcuma longa Linn.: Phytochemical, pharmacological,
and molecular study. IJGP 2017, 11, S671.
59. Ahmed, T.; Gilani, A.H.; Hosseinmardi, N.; Semnanian, S.; Enam, S.A.; Fathollahi, Y. Curcuminoids rescue
long-term potentiation impaired by amyloid peptide in rat hippocampal slices. Synapse 2011, 65, 572–582.
[CrossRef]
60. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; et al. Curcumin inhibits
formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem.
2005, 280, 5892–5901. [CrossRef]
61. Yanagisawa, D.; Taguchi, H.; Yamamoto, A.; Shirai, N.; Hirao, K.; Tooyama, I. Curcuminoid binds to
amyloid-beta1-42 oligomer and fibril. J. Alzheimer’s Dis. 2011, 24, 33–42. [CrossRef]
62. Ono, K.; Hasegawa, H.; Naiki, M.; Yamada, M. Curcumin has potentanti-amyloidogenic effects for Alzheimer’s
beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742–750. [CrossRef] [PubMed]
63. Zhang, L.; Fiala, M.; Cashman, J.; Sayre, J.; Espinosa, A.; Mahanian, M.; Zaghi, J.; Badmaev, V.; Graves, M.C.;
Bernard, G.; et al. Curcuminoids enhanceamyloid-beta uptake by macrophages of Alzheimer’s disease
patients. J. Alzheimers Dis. 2006, 10, 1–7. [CrossRef] [PubMed]
64. Kim, H.; Park, B.S.; Lee, K.G.; Choi, C.Y.; Jang, S.S.; Kim, Y.H.; Lee, S.E. Effects of naturally occurring
compounds on fibril formation and oxidative stress of beta-amyloid. J. Agric. Food Chem. 2005, 53, 8537–8541.
[CrossRef]
65. Shimmyo, Y.; Kihara, T.; Akaike, A.; Niidome, T.; Sugimoto, H. Epigallocatechin-3-gallate and curcumin
suppress amyloid beta-inducedbeta-site APP cleaving enzyme-1 upregulation. Neuroreport 2008, 19,
1329–1333. [CrossRef] [PubMed]
66. Liu, H.Y.; Fu, X.; Li, Y.F.; Li, X.L.; Ma, Z.Y.; Zhang, Y.; Gao, Q.C. miR-15b-5p targeting amyloid precursor
protein is involved in the anti-amyloid eflect of curcumin in swAPP695-HEK293 cells. Neural Regen. Res.
2019, 14, 1603–1609.
67. Ahmed, T.; Enam, S.A.; Gilani, A.H. Curcuminoids enhance memory in an amyloid-infused rat model of
Alzheimer’s disease. Neuroscience 2010, 169, 1296–1306. [CrossRef]
68. Garcia-Alloza, M.; Borrelli, L.A.; Rozkalne, A.; Hyman, B.T.; Bacskai, B.J. Curcumin labels amyloid pathology
in vivo, disrupts existing plaques, andpartially restores distorted neurites in an Alzheimer mouse model.
J. Neurochem. 2007, 102, 1095–1104. [CrossRef]
69. Wang, Y.J.; Thomas, P.; Zhong, J.H.; Bi, F.F.; Kosaraju, S.; Pollard, A.; Fenech, M.; Zhou, X.F. Consumption of
grape seed extract prevents amyloid-betadeposition and attenuates inflammation in brain of an Alzheimer’s
diseasemouse. Neurotox. Res. 2009, 15, 3–14. [CrossRef]
70. Ishrat, T.; Hoda, M.N.; Khan, M.B.; Yousuf, S.; Ahmad, M.; Khan, M.M.; Ahmad, A.; Islam, F. Amelioration
of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer’s
type (SDAT). Eur. Neuropsychopharmacol. 2009, 19, 636–647. [CrossRef]
71. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces
oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21, 8370–8377.
[CrossRef]
72. Kumar, J.; Park, K.C.; Awasthi, A.; Prasad, B. Silymarin extends lifespan and reduces proteotoxicity in C.
elegans Alzheimer’s model. CNS Neurol. Disord. Drug Targets 2015, 14, 295–302. [CrossRef] [PubMed]
73. Habtemariam, S. Protective Effects of Caffeic Acid and the Alzheimer’s Brain: An Update. Mini Rev. Med.
Chem. 2017, 17, 667–674. [CrossRef]
74. Ng, T.P.; Chiam, P.C.; Lee, T.; Chua, H.C.; Lim, L.; Kua, E.H. Curry consumption and cognitive function in
the elderly. Am. J. Epidemiol. 2006, 164, 898–906. [CrossRef] [PubMed]
75. Kandimalla, R.J.; Prabhakar, S.; Binukumar, B.K.; Wani, W.Y.; Sharma, D.R.; Grover, V.K.; et al. Cerebrospinal
fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer’s disease patients.
Neurosci. Lett. 2011, 487, 134–138. [CrossRef] [PubMed]
Antioxidants 2019, 8, 608 13 of 16
76. Kandimalla, R.J.; Prabhakar, S.; Binukumar, B.K.; Wani, W.Y.; Gupta, N.; Sharma, D.R.; et al. Apo-Eε4 allele
in conjunction with Aβ42 and tau in CSF: Biomarker for Alzheimer’s disease. Curr. Alzheimer Res. 2011, 8,
187–196. [CrossRef]
77. Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.;
Heath, D.D.; Apostolova, L.G.; et al. Oral curcumin for Alzheimer’s disease: Tolerability and efficacy in a
24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res. Ther. 2012, 4, 43. [CrossRef]
78. Hishikawa, N.; Takahashi, Y.; Amakusa, Y.; Tanno, Y.; Tuji, Y.; Niwa, H.; Krishna, U.K. Effects of turmeric
on Alzheimer’s disease with behavioral and psychological symptoms of dementia. Ayu 2012, 33, 499–504.
[CrossRef]
79. Baum, L.; Lam, C.W.K.; Cheung, S.K.-K.; Kwok, T.; Lui, V.; Tsoh, J.; Lam, L.; Leung, V.; Hui, E.; Ng, C.; et al.
Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients with
Alzheimer Disease. J. Clin. Psychopharmacol. 2008, 28, 110–113. [CrossRef]
80. Mira, L.; Silva, M.; Manso, C.F. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem.
Pharmacol. 1994, 48, 753–759. [CrossRef]
81. Borah, A.; Paul, R.; Choudhury, S.; Choudhury, A.; Bhuyan, B.; Das Talukdar, A.; Dutta Choudhury, M.;
Mohanakumar, K.P. Neuroprotective potential of silymarin against CNS disorders:insight into the pathways
and molecular mechanisms of action. CNS Neurosci. Ther. 2013, 19, 847–853. [CrossRef]
82. Devi, K.P.; Malar, D.S.; Braidy, N.; Nabavi, S.M.; Nabavi, S.F. A Mini Review on the Chemistry and
Neuroprotective Effects of Silymarin. Curr. Drug Targets 2017, 18, 1529–1536. [CrossRef] [PubMed]
83. Baluchnejadmojarad, T.; Roghani, M.; Mafakheri, M. Neuroprotective effect of Silymarin in
6-hydroxydopamine hemi-parkinsonian rat: Involvement of estrogen receptors and oxidative stress. Neurosci.
Lett. 2010, 480, 206–210. [CrossRef] [PubMed]
84. Lu, P.; Mamiya, T.; Lu, L.L.; Mouri, A.; Niwa, M.; Hiramatsu, M.; Zou, L.B.; Nagai, T.; Ikejima, T.; Nabeshima, T.
Silibinin attenuates amyloid β (25–35) peptide-induced memory impairments: Implication of inducible
nitric-oxide synthase and tumor necrosis factor-alpha in mice. J. Pharmacol. Exp. Ther. 2009, 331, 319–326.
[PubMed]
85. Yin, F.; Liu, J.; Ji, X.; Wang, Y.; Zidichouski, J.; Zhang, J. Silibinin: A novel inhibitor of Ab aggregation.
Neurochem. Int. 2011, 58, 399–403. [CrossRef] [PubMed]
86. Murata, N.; Murakami, K.; Ozawa, Y.; Kinoshita, N.; Irie, K.; Shirasawa, T.; Shimizu, T. Silymarin attenuated
the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse
model. Biosci. Biotechnol. Biochem. 2010, 74, 2299–2306. [CrossRef]
87. Wang, M.J.; Lin, W.W.; Chen, H.L.; Chang, Y.H.; Ou, H.C.; Kuo, J.S.; Hong, J.S.; Jeng, K.C. Silymarin protects
dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation.
Eur. J. Neurosci. 2002, 16, 2103–2112. [CrossRef]
88. Reid, C.; Edwards, J.; Wang, M.; Manybeads, Y.; Mike, L.; Martinez, N.; et al. Prevention by a
silymarin/phospholipid compound of ethanol-induced social learning deficits in rats. Planta Med. 1999, 65,
421–424. [CrossRef]
89. Galhardi, F.; Mesquita, K.; Monserrat, J.M.; Barros, D.M. Effect of silymarin on biochemical parameters of
oxidative stress in aged and young rat brain. Food Chem. Toxicol. 2009, 47, 2655–2660. [CrossRef]
90. Wang, C.; Wang, Z.; Zhang, X.; Dong, L.; Xing, Y.; Li, Y.; Liu, Z.; Chen, L.; Qiao, H.; Wang, L.; et al.
Protection by silibinin against experimental ischemic stroke: Up-regulated pAkt, pmTOR, HIF-1a and Bcl-2,
down-regulated Bax, NF-jB expression. Neurosci. Lett. 2012, 529, 45–50. [CrossRef]
91. Song, X.; Liu, B.; Cui, L.; Zhou, B.; Liu, W.; Xu, F.; et al. Silibinin ameliorates anxiety/depression-like behaviors
in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus.
Physiol. Behav. 2017, 179, 487–493. [CrossRef]
92. Raza, S.S.; Khan, M.M.; Ashafaq, M.; Ahmad, A.; Khuwaja, G.; Khan, A.; Siddiqui, M.S.; Safhi, M.M.;
Islam, F. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia:
A behavioral, biochemical andimmunohistological study in Wistar rats. J. Neurol. Sci. 2011, 309, 45–54.
[CrossRef] [PubMed]
93. Duan, S.; Guan, X.; Lin, R.; Liu, X.; Yan, Y.; Lin, R.; Zhang, T.; Chen, X.; Huang, J.; Sun, X.; et al. Silibinin
inhibits acetylcholinesterase activity and amyloidβ peptide aggregation: A dual-target drug for the treatment
of Alzheimer’s disease. Neurobiol. Aging 2015, 36, 1792–1807. [CrossRef] [PubMed]
Antioxidants 2019, 8, 608 14 of 16
94. Yön, B.; Belviranlı, M.; Okudan, N. The effect of silymarin supplementation on cognitive impairment induced
by diabetes in rats. J. Basic Clin. Physiol. Pharmacol. 2019, 24, 30–34. [CrossRef] [PubMed]
95. Seidlova-Wuttke, D.; Becker, T.; Christoffel, V.; Jarry, H.; Wuttke, W. Silymarin is a selective estrogen receptor
beta (ERbeta) agonist and has estrogenic effects in the metaphysis of the femur but no or antiestrogenic
effects in the uterus of ovariectomized (ovx) rats. J. Steroid Biochem. Mol. Biol. 2003, 86, 179–188. [CrossRef]
96. Pliskova, M.; Vondracek, J.; Kren, V.; Gazák, R.; Sedmera, P.; Walterová, D.; Psotová, J.; Simánek, V.;
Machala, M. Effects of Silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl
hydrocarbon receptor activation. Toxicology 2005, 215, 80–89. [CrossRef]
97. De Groot, H.; Rauen, U. Tissue injury by reactive oxygen species and the protective effects of flavonoids.
Fundam. Clin. Pharmacol. 1998, 12, 249–255. [CrossRef]
98. Trouillas, P.; Marsal, P.; Svobodová, A.; Vostálová, J.; Gazák, R.; Hrbác, J.; et al. Mechanism of the antioxidant
action of silybin and 2,3-dehydrosilybin flavonolignans: A joint experimental and theoretical study. J. Phys.
Chem. A 2008, 112, 1054–1063. [CrossRef]
99. Valenzuela, A.; Aspillaga, M.; Vial, S.; Guerra, R. Selectivity of silymarin on the increase of the glutathione
content in different tissues of the rat. Planta Med. 1989, 55, 420–422. [CrossRef]
100. Müzes, G.; Deák, G.; Láng, I.; Nékám, K.; Gergely, P.; Fehér, J. Effect of the bioflavonoid silymarin on the
in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol. Hung. 1991, 78, 3–9.
101. Wang, Q.; Zou, L.; Liu, W.; Hao, W.; Tashiro, S.; Onodera, S.; et al. Inhibiting NF-kappaB activation and ROS
production are involved in the mechanism of silibinin’s protection against d-galactose-induced senescence.
Pharmacol. Biochem. Behav. 2011, 98, 140–149. [CrossRef]
102. Lu, P.; Mamiya, T.; Lu, L.L.; Mouri, A.; Zou, L.; Nagai, T.; et al. Silibinin prevents amyloid beta peptide-induced
memory impairment and oxidative stress in mice. Br. J. Pharmacol. 2009, 157, 1270–1277. [CrossRef] [PubMed]
103. Tota, S.; Kamat, P.K.; Shukla, R.; Nath, C. Improvement of brain energy metabolism and cholinergic functions
contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav.
Brain Res. 2011, 221, 207–215. [CrossRef] [PubMed]
104. Shen, L.; Liu, L.; Li, X.Y.; Ji, H.F. Regulation of gut microbiota in Alzheimer’s disease mice by silibinin
and silymarin and their pharmacological implications. Appl. Microbiol. Biotechnol. 2019, 103, 7141–7149.
[CrossRef] [PubMed]
105. De Andrade Teles, R.B.; Diniz, T.C.; Costa Pinto, T.C.; de Oliveira Júnior, R.G.; Gama, E.; Silva, M.; de Lavor, M.;
Fernandes, A.W.C.; de Oliveira, A.P.; de Almeida Ribeiro, F.P.R.; et al. Flavonoids as Therapeutic Agents
in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences. Oxid. Med. Cell.
Longev. 2018, 2018, 7043213. [CrossRef]
106. Liang, N.; Kitts, D.D. Role of Chlorogenic Acids in Controlling Oxidative and Inflammatory Stress Conditions.
Nutrients 2015, 8, 16. [CrossRef]
107. Huang, Y.; Jin, M.; Zhang, J.; Chen, M.; Ouyang, Y.; Liu, A.; Chao, X.; Liu, P.; Liu, J.; Ramassamy, C.; et al.
Protective effects of caffeic acid and caffeic acid phenethyl ester against acrolein-induced neurotoxicity in
HT22 mouse hippocampal cells. Neurosci. Lett. 2013, 535, 146–151. [CrossRef]
108. Cho, E.S.; Jang, Y.J.; Hwang, M.K.; Kang, N.J.; Lee, K.W.; Lee, H.J. Attenuation of oxidative neuronal cell
death by coffee phenolic phytochemicals. Mutat. Res. 2009, 661, 18–24. [CrossRef]
109. Kumar, V.; Giacobini, E. Cerebrospinal fluid choline, and acetylcholinesterase activity in familial vs.
non-familial Alzheimer’s disease patients. Arch. Gerontol. Geriatr. 1988, 7, 111–117. [CrossRef]
110. Orhan, I.; Sener, B.; Choudhary, M.I.; Khalid, A. Acetylcholinesterase and butyrylcholinesterase inhibitory
activity of some Turkish medicinal plants. J. Ethnopharmacol. 2004, 91, 57–60. [CrossRef]
111. Oboh, G.; Agunloye, O.M.; Akinyemi, A.J.; Ademiluyi, A.O.; Adefegha, S.A. Comparative study on the
inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer’s disease and some
pro-oxidant induced oxidative stress in rats’ brain-in vitro. Neurochem. Res. 2013, 38, 413–419. [CrossRef]
112. Han, J.; Miyamae, Y.; Shigemori, H.; Isoda, H. Neuroprotective effect of 3,5-di-o-caffeoylquinic acid on
SH-SY5Y cells and senescense-accelerated-prone mice 8 through the up-regulation of phosphoglycertate
kinase 1. Neuroscience 2010, 169, 1039–1045. [CrossRef] [PubMed]
113. Miyamae, Y.; Kurisu, M.; Murakami, K.; Han, J.; Isoda, H.; Irie, K.; et al. Protective effects of caffeoylquinic
acids on the aggregation and neurotoxicityof the 42-residue amyloid β-protein. Bioorg. Med. Chem. 2012, 20,
5844–5849. [CrossRef] [PubMed]
Antioxidants 2019, 8, 608 15 of 16
114. Chang, W.; Huang, D.; Lo, Y.M.; Tee, Q.; Kuo, P.; Wu, J.S.; Huang, W.; Shen, S. Protective Effect of Caffeic
Acid against Alzheimer’s Disease Pathogenesis via Modulating Cerebral Insulin Signaling, β-Amyloid
Accumulation, and Synaptic Plasticity in Hyperinsulinemic Rats. J. Agric. Food Chem. 2019, 67, 7684–7693.
[CrossRef]
115. Kwon, S.H.; Lee, H.K.; Kim, J.A.; Hong, S.I.; Kim, H.C.; Jo, T.H.; et al. Neuroprotective effects of chlorogenic
acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice.
Eur. J. Pharmacol. 2010, 649, 210–217. [CrossRef] [PubMed]
116. Ishida, K.; Yamamoto, M.; Misawa, K.; Nishimura, H.; Misawa, K.; Ota, N.; et al. Coffee polyphenols prevent
cognitive dysfunction and suppress amyloid β plaques in APP/PS2 transgenic mouse. Neurosci. Res. 2019.
[CrossRef]
117. Panza, F.; Solfrizzi, V.; Barulli, M.R.; Bonfiglio, C.; Guerra, V.; Osella, A.; et al. Coffee, tea, and caffeine
consumption and prevention of late-life cognitive decline and dementia: A systematic review. J. Nutr. Health
Aging 2015, 19, 313–328. [CrossRef]
118. Solfrizzi, V.; Panza, F.; Imbimbo, B.P.; D’Introno, A.; Galluzzo, L.; Gandin, C.; et al. Italian Longitudinal
Study on Aging Working Group. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment:
The Italian Longitudinal Study on Aging. J. Alzheimers Dis. 2015, 47, 889–899. [CrossRef]
119. Kim, J.W.; Byun, M.S.; Yi, D.; Lee, J.H.; Jeon, S.Y.; Jung, G.; Lee, H.N.; Sohn, B.K.; Lee, J.Y.; Kim, Y.K.; et al.
Coffee intake and decreased amyloid pathology in human brain. Transl. Psychiatry 2019, 9, 270. [CrossRef]
120. Eskelinen, M.H.; Ngandu, T.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Midlife coffee and tea drinking and
the risk of late-life dementia: A population-based CAIDE study. J. Alzheimers Dis. 2009, 16, 85–91. [CrossRef]
121. Kato, M.; Ochiai, R.; Kozuma, K.; Sato, H.; Katsuragi, Y. Effect of Chlorogenic Acid Intake on Cognitive
Function in the Elderly: A Pilot Study. Evid. Based Complement. Altern. Med. 2018, 2018, 8608497. [CrossRef]
122. Saitou, K.; Ochiai, R.; Kozuma, K.; Sato, H.; Koikeda, T.; Osaki, N.; Katsuragi, Y. Effect of Chlorogenic Acids
on Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2018, 10, 1337.
[CrossRef]
123. Olasehinde, T.A.; Olaniran, A.O.; Okoh, A.I. Therapeutic potentials of microalgae in the treatment of
Alzheimer’s disease. Molecules 2017, 22, 480. [CrossRef] [PubMed]
124. Mutanda, T.; Ramesh, D.; Karthikeyan, S.; Kumari, S.; Anandraj, A.; Bux, F. Bioprospecting for hyper-lipid
producing microalgal strains for sustainable biofuel production. Bioresour. Technol. 2011, 102, 57–70.
[CrossRef] [PubMed]
125. Raposo, M.F.; Morais, R.M.; Morais, A.M.M. Health applications of bioactive compounds from marine
microalgae. Life Sci. 2013, 93, 479–486. [CrossRef] [PubMed]
126. Guzman, S.; Gato, A.; Calleja, J.M. Antiinflammatory, analgesic and free radical scavenging activities of
the marine microalgae Chlorella stigmatophora and Phaeodactylumtricornutum. Phytother. Res. 2001, 15,
224–230. [CrossRef] [PubMed]
127. Gardeva, E.; Toshkova, R.; Minkova, K.; Gigova, L. Cancer protective action of polysaccharide derived from
microalga Porphyridiumcruentum-A biological background. Biotechnol. Equip. 2009, 23, 783–787. [CrossRef]
128. Chidambara-Murthy, K.N.; Vanitha, A.; Rajesha, J.; Mahadeva-Swamy, M.; Sowmya, P.R.; Ravishankar, G.A.
In vivo antioxidant activity of carotenoids from Dunaliella salina—A green microalga. Life Sci. 2005, 76,
1382–1390.
129. Christaki, E.; Florou-Paneri, P.; Bonos, E. Microalgae: A novel ingredient in nutrition. Int. J. Food Sci. Nutr.
2011, 62, 794–799. [CrossRef] [PubMed]
130. Romay, C.; Armesto, J.; Remirez, D.; González, R.; Ledon, N.; García, I. Antioxidant and anti-inflammatory
properties of C-phycocyanin from blue-green algae. Inflamm. Res. 1998, 47, 36–41. [CrossRef] [PubMed]
131. Romay, C.; Ledón, N.; González, R. Further studies on anti-inflammatory activity of phycocyanin in some
animal models of inflammation. Inflamm. Res. 1998, 47, 334–338. [CrossRef]
132. Yun, H.; Kim, I.; Kwon, S.H.; Kang, J.S.; Om, A.S. Protective effect of chlorella vulgaris against lead-induced
oxidative stress in rat brains. J. Health Sci. 2011, 57, 245–254. [CrossRef]
133. Miranda, M.S.; Cintra, R.G.; Barros, S.B.; Mancini, F.J. Antioxidant activity of the microalga Spirulina maxima.
Braz. J. Med. Biol. Res. 1998, 31, 1075–1079. [CrossRef] [PubMed]
134. El-Baky, H.H.A.; El Baz, F.K.; El-Baroty, G.S. Production of phenolic compounds from Spirulina maxima
microalgae and its protective effects. Afr. J. Biotechnol. 2009, 8, 7059–7067.
Antioxidants 2019, 8, 608 16 of 16
135. Tan, J.W.; Kim, M.K. Neuroprotective effects of biochanin A against β-amyloid-induced neurotoxicity in
PC12 cells via a mitochondrial-dependent apoptosis pathway. Molecules 2016, 21, 548. [CrossRef] [PubMed]
136. Kushak, R.I.; Drapeau, C.; Winter, H.D. The effect of blue-green algae Aphanizomenon Flos Aquae on
nutrient assimilation in rats. JANA 2001, 3, 35–39.
137. Hille, R. Molybdenum and tungsten in biology. Trends Biochem. Sci. 2002, 27, 360–367. [CrossRef]
138. Pushie, M.J.; George, G.N. Spectroscopic studies of molybdenum and tungsten enzymes. Coord. Chem. Rev.
2011, 255, 1055–1084. [CrossRef]
139. Benedetti, S.; Benvenuti, F.; Scoglio, S.; Canestrari, F. Oxygen radical absorbance capacity of phycocyanin
and phycocyanobilin from the food supplement Aphanizomenon flos-aquae. J. Med. Food 2010, 13, 223–227.
[CrossRef]
140. Cavalchini, A.; Scoglio, S. Complementary treatment of psoriasis with an AFA-phyocyanins product:
A preliminary 10-cases study. Intern. Med. J. 2009, 16, 3.
141. Nuzzo, D.; Presti, G.; Picone, P.; Galizzi, G.; Gulotta, E.; Giuliano, S.; et al. Effects of the Aphanizomenon
flos-aquae Extract (Klamin®) on a Neurodegeneration Cellular Model. Oxid. Med. Cell. Longev. 2018, 2018,
9089016. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
